IPSC-DAPs (allogenic)

induced pluripotent stem cell-derived dopamine precursor cells · iCamuno Biotherapeutics Ltd

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for IPSC-DAPs (allogenic), covering 2026-02-11 to 2026-02-11. Get the full timeline:

Most recent: Clinical Trial Update: Stereotactic Intracerebral Injection of Allogenic IPSC-DAPs in Patients With Parkinson's Disease [Phase 1]